Sage Gets $3 Billion Endorsement of Its Depression Drugs From Biogen
Shaken by a government advisory panel’s poor review of its experimental treatment for Alzheimer’s disease, Biogen announced a team-up Friday with Sage Therapeutics. Biogen has committed up to $3.1 billion to the development and marketing of two drugs that Sage is developing for depression and neurological disorders. If successful, the drugs would shore up Biogen’s … Read more